AbbVie (NYSE:ABBV) announced on Thursday that the company has reached settlements with all generic drugmakers to resolve ...

The biopharmaceutical company doesn’t expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

Penn researchers say they will pursue larger-scale studies to continue testing whether hydroxychloroquine and everolimus can ...

Rapamycin is an immune suppressant often used in organ transplant patients, but it has also been shown to extend life in ...

The news that the brand is protected from generics for more than a decade "gives AbbVie a kind of tremendous runway," to sell ...

Shares of AbbVie closed at a record after it struck a deal that will extend patent exclusivity for its blockbuster autoimmune ...

One of the great triumphs of health policy is America’s generic drug market. Nine out of ten U.S. prescriptions are filled with generics. That overwhelming share saves patients and taxpayers hundreds ...

The $5.7 billion Indian drug maker is building capacity to tap into the massive opportunity from GLP-1 drugs to open up in ...

President Donald Trump has plastered taxes on products from almost every country on earth. He’s targeted specific imports, ...

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from ...